Skip to main navigation
Skip to search
Skip to main content
UT MD Anderson Cancer Center Home
Help & FAQ
Link opens in a new tab
Search content at UT MD Anderson Cancer Center
Home
Profiles
Research units
Equipment
Research output
Activities
Prizes
Treatment of acute myelogenous leukemia in the elderly
R. E. Champlin
, J. L. Gajewski
, D. W. Golde
Research output
:
Contribution to journal
›
Review article
›
peer-review
43
Link opens in a new tab
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Treatment of acute myelogenous leukemia in the elderly'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Acute Myeloid Leukemia
100%
Chemotherapy
50%
Remission
50%
Intravenous Infusion
50%
Performance Status
50%
Intensive Chemotherapy
50%
Elderly Patients
50%
Daunorubicin
50%
Cytarabine
50%
Intensive Regimens
50%
Consolidation Chemotherapy
50%
Remission Induction
50%
Low-dose Chemotherapy
50%
Debilitated Patients
50%
Standard Treatment Regimen
50%
Medicine and Dentistry
Acute Myeloid Leukemia
100%
Chemotherapy
100%
Intravenous Drug Administration
50%
Cytarabine
50%
Induction Chemotherapy
50%
Elderly Patient
50%
Spontaneous Remission
50%
Liposomal Daunorubicin
50%
Consolidation Chemotherapy
50%
Low-Dose Chemotherapy
50%
Nursing and Health Professions
Acute Myeloid Leukemia
100%
Chemotherapy
100%
Remission
66%
Low Drug Dose
33%
Elderly Patient
33%
Cytarabine
33%
Induction Chemotherapy
33%
Intravenous Drug Administration
33%
Consolidation Chemotherapy
33%
Daunorubicin
33%
Pharmacology, Toxicology and Pharmaceutical Science
Acute Myeloid Leukemia
100%
Chemotherapy Regimen
100%
Remission
40%
Cytarabine
20%
Daunorubicin
20%